GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lianluo Smart Ltd (NAS:LLIT) » Definitions » Debt-to-EBITDA

Lianluo Smart (Lianluo Smart) Debt-to-EBITDA : -0.74 (As of Dec. 2020)


View and export this data going back to 2010. Start your Free Trial

What is Lianluo Smart Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lianluo Smart's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2020 was $1.78 Mil. Lianluo Smart's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2020 was $0.00 Mil. Lianluo Smart's annualized EBITDA for the quarter that ended in Dec. 2020 was $-2.41 Mil. Lianluo Smart's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2020 was -0.74.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Lianluo Smart's Debt-to-EBITDA or its related term are showing as below:

LLIT' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.71   Med: -0.02   Max: 495.6
Current: -0.68

During the past 13 years, the highest Debt-to-EBITDA Ratio of Lianluo Smart was 495.60. The lowest was -0.71. And the median was -0.02.

LLIT's Debt-to-EBITDA is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 1.21 vs LLIT: -0.68

Lianluo Smart Debt-to-EBITDA Historical Data

The historical data trend for Lianluo Smart's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lianluo Smart Debt-to-EBITDA Chart

Lianluo Smart Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -0.41 - -0.40 -0.71

Lianluo Smart Semi-Annual Data
Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.14 -4.51 -0.77 -0.74

Competitive Comparison of Lianluo Smart's Debt-to-EBITDA

For the Medical Devices subindustry, Lianluo Smart's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lianluo Smart's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Lianluo Smart's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Lianluo Smart's Debt-to-EBITDA falls into.



Lianluo Smart Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Lianluo Smart's Debt-to-EBITDA for the fiscal year that ended in Dec. 2020 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.784 + 0) / -2.523
=-0.71

Lianluo Smart's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2020 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(1.784 + 0) / -2.412
=-0.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2020) EBITDA data.


Lianluo Smart  (NAS:LLIT) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Lianluo Smart Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Lianluo Smart's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Lianluo Smart (Lianluo Smart) Business Description

Traded in Other Exchanges
N/A
Address
No. 10 Baifuquan Roa, Room 611, 6th Floor, BeiKong Technology Building, Changping District, Beijing, CHN, 102200
Lianluo Smart Ltd design, develop and market medical products and medical components. The company focuses on the business sectors of; Medical Equipment and the provision of Obstructive Sleep Apnea Syndrome (OSAS) diagnostic services. Its products include wearable sleep respiratory devices, medical devices for cardiopulmonary resuscitation, DHR998 Plus, and others. The company sells its products to distributors, hospitals and physical examination centers, and others. All of its revenue is generated from China.